Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of the studies included in this meta-analysis

From: Efficacy and safety of stem cell therapy in patients with dilated cardiomyopathy: a systematic appraisal and meta-analysis

Authors/year of publication Country Male (%) Mean age Intervention Follow-up Study design Outcomes assessed
Stem cell Control
Seth/2010 [20] India 83.9 Stem cell: 45 ± 15 years
Control: 49 ± 9 years
41 40 36 M RCT Mortality, LVEF, LVEDCS, and LVESV
Vrtovec/2011 [14] USA 79 53 ± 9 years 28 27 12 M RCT Mortality, LVEF, LVEDCS, and 6-min-walk test
Vrtovec/2013 [21] USA 81 54 ± 9 years 55 55 60 M RCT Mortality, LVEF, LVEDCS, and 6-min-walk test
Henry/2014 [22] USA 68.9 Stem cell: 57.9 ± 11 years
Control: 52.3 ± 11 years
18 11 12 M RCT Mortality, LVEF, LVESV, and 6-min-walk test
Sant Anna/2014 [23] Brazil 60 Stem cell: 48.3 ± 8.71 years
Control: 51.6 ± 7.79 years
20 10 12 M RCT Mortality, LVEF, LVESV, LVEDCS, and 6-min-walk test
Hamshere/2015 [26] UK 75.8 Stem cell: 57.67 ± 12.32 years
Control: 56.79 ± 9.84 years
15 14 12 M RCT Mortality, LVEF, LVEDCS, and LVESV
Martino/2015 [24] Brazil 70.6 Stem cell: 51 ± 11.1 years
Control: 49.6 ± 11.1 years
82 78 12 M RCT Mortality, LVEF, LVESV, and 6-min-walk test
Xiao/2017 [25] China 75.6 Stem cell: 51.6 ± 12.2 years
Control: 54.4 ± 11.6 years
17 20 12 M RCT Mortality, LVEF, LVEDCS, and 6-min-walk test
  1. LVEDCS left ventricular end-diastolic chamber size, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, M months, NA not available, RCT randomized controlled trial